BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 36528478)

  • 21. Substantial family history of prostate cancer in black men recruited for prostate cancer screening: results from the Prostate Cancer Risk Assessment Program.
    Mastalski K; Coups EJ; Ruth K; Raysor S; Giri VN
    Cancer; 2008 Nov; 113(9):2559-64. PubMed ID: 18816608
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 23. How can we recruit more men of African or African-Caribbean ancestry into our research? Co-creating a video to raise awareness of prostate cancer risk and the PROFILE study.
    Hainsworth E; McGrowder E; McHugh J; Bancroft E; Mahabir S; Webber W; Eeles R; Cruickshank S
    Res Involv Engagem; 2022 Apr; 8(1):14. PubMed ID: 35436967
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The feasibility of epidemiological research on prostate cancer in African men in Ibadan, Nigeria.
    Agalliu I; Adebiyi AO; Lounsbury DW; Popoola O; Jinadu K; Amodu O; Paul S; Adedimeji A; Asuzu C; Asuzu M; Ogunbiyi OJ; Rohan T; Shittu OB
    BMC Public Health; 2015 Apr; 15():425. PubMed ID: 25927535
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structured Population-based Prostate-specific Antigen Screening for Prostate Cancer: The European Association of Urology Position in 2019.
    Gandaglia G; Albers P; Abrahamsson PA; Briganti A; Catto JWF; Chapple CR; Montorsi F; Mottet N; Roobol MJ; Sønksen J; Wirth M; van Poppel H
    Eur Urol; 2019 Aug; 76(2):142-150. PubMed ID: 31092338
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of Inherited Mutations in DNA Repair Genes with Localized Prostate Cancer.
    Lee DJ; Hausler R; Le AN; Kelly G; Powers J; Ding J; Feld E; Desai H; Morrison C; Doucette A; Gabriel P; Genetics Center R; Judy RL; Weaver J; Kember R; Damrauer SM; Rader DJ; Domchek SM; Narayan V; Schwartz LE; Maxwell KN
    Eur Urol; 2022 Jun; 81(6):559-567. PubMed ID: 34711450
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic impact of definitive local therapy of the primary tumor in men with metastatic prostate cancer at diagnosis: A population-based, propensity score analysis.
    Antwi S; Everson TM
    Cancer Epidemiol; 2014 Aug; 38(4):435-41. PubMed ID: 24802851
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hereditary Predisposition to Prostate Cancer: From Genetics to Clinical Implications.
    Brandão A; Paulo P; Teixeira MR
    Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708810
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of prostate cancer family history with histopathological and clinical characteristics of prostate tumors.
    Spangler E; Zeigler-Johnson CM; Malkowicz SB; Wein AJ; Rebbeck TR
    Int J Cancer; 2005 Jan; 113(3):471-4. PubMed ID: 15455347
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of germline mutations in the BRCA1/2 and mismatch repair genes in men ascertained for early-onset and/or familial prostate cancer.
    Maia S; Cardoso M; Paulo P; Pinheiro M; Pinto P; Santos C; Pinto C; Peixoto A; Henrique R; Teixeira MR
    Fam Cancer; 2016 Jan; 15(1):111-21. PubMed ID: 26289772
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Disease-specific survival of men with prostate cancer detected during the screening interval: results of the European randomized study of screening for prostate cancer-Rotterdam after 11 years of follow-up.
    Zhu X; van Leeuwen PJ; Bul M; Otto SJ; de Koning HJ; Bangma CH; Schröder FH; Roobol MJ
    Eur Urol; 2011 Aug; 60(2):330-6. PubMed ID: 21601352
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Performance of Three Inherited Risk Measures for Predicting Prostate Cancer Incidence and Mortality: A Population-based Prospective Analysis.
    Shi Z; Platz EA; Wei J; Na R; Fantus RJ; Wang CH; Eggener SE; Hulick PJ; Duggan D; Zheng SL; Cooney KA; Isaacs WB; Helfand BT; Xu J
    Eur Urol; 2021 Mar; 79(3):419-426. PubMed ID: 33257031
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prostate Specific Antigen-Growth Curve Model to Predict High-Risk Prostate Cancer.
    Shoaibi A; Rao GA; Cai B; Rawl J; Haddock KS; Hébert JR
    Prostate; 2017 Feb; 77(2):173-184. PubMed ID: 27699819
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PRState: Incorporating genetic ancestry in prostate cancer risk scores for men of African ancestry.
    Pagadala MS; Linscott JA; Talwar JV; Seibert TM; Rose B; Lynch J; Panizzon M; Hauger R; Hansen MH; Sammon JD; Hayn MH; Kader K; Carter H; Ryan ST
    BMC Cancer; 2022 Dec; 22(1):1289. PubMed ID: 36494783
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Men with family history of prostate cancer have a higher risk of disease recurrence after radical prostatectomy.
    Thalgott M; Kron M; Brath JM; Ankerst DP; Thompson IM; Gschwend JE; Herkommer K
    World J Urol; 2018 Feb; 36(2):177-185. PubMed ID: 29164326
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Coffee Intake, Caffeine Metabolism Genotype, and Survival Among Men with Prostate Cancer.
    Gregg JR; Kim J; Logothetis C; Hanash S; Zhang X; Manyam G; Muir K; ; Giles GG; Stanford JL; Berndt SI; Kogevinas M; Brenner H; Eeles RA; ; Wei P; Daniel CR
    Eur Urol Oncol; 2023 Jun; 6(3):282-288. PubMed ID: 35995710
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mortality Among Men with Advanced Prostate Cancer Excluded from the ProtecT Trial.
    Johnston TJ; Shaw GL; Lamb AD; Parashar D; Greenberg D; Xiong T; Edwards AL; Gnanapragasam V; Holding P; Herbert P; Davis M; Mizielinsk E; Lane JA; Oxley J; Robinson M; Mason M; Staffurth J; Bollina P; Catto J; Doble A; Doherty A; Gillatt D; Kockelbergh R; Kynaston H; Prescott S; Paul A; Powell P; Rosario D; Rowe E; Donovan JL; Hamdy FC; Neal DE;
    Eur Urol; 2017 Mar; 71(3):381-388. PubMed ID: 27720537
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Three-month posttreatment prostate-specific antigen level as a biomarker of treatment response in patients with intermediate-risk or high-risk prostate cancer treated with androgen deprivation therapy and radiotherapy.
    Bryant AK; D'Amico AV; Nguyen PL; Einck JP; Kane CJ; McKay RR; Simpson DR; Mundt AJ; Murphy JD; Rose BS
    Cancer; 2018 Jul; 124(14):2939-2947. PubMed ID: 29727915
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk of prostate cancer associated with a family history in an era of rapid increase in prostate cancer diagnosis (Australia).
    Staples MP; Giles GG; English DR; McCredie MR; Severi G; Cui JS; Hopper JL
    Cancer Causes Control; 2003 Mar; 14(2):161-6. PubMed ID: 12749721
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Single-Nucleotide Polymorphism-Based Genetic Risk Score and Patient Age at Prostate Cancer Diagnosis.
    Na R; Labbate C; Yu H; Shi Z; Fantus RJ; Wang CH; Andriole GL; Isaacs WB; Zheng SL; Helfand BT; Xu J
    JAMA Netw Open; 2019 Dec; 2(12):e1918145. PubMed ID: 31880795
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.